These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36070428)

  • 1. Efficacy analysis following polymer coated drug eluting stent and bare metal stent deployment for femoropopliteal arterial disease.
    Shehada Y; Bisdas T; Argyriou A; Torsello G; Tsilimparis N; Beropoulis E; Stavroulakis K
    Vascular; 2024 Feb; 32(1):102-109. PubMed ID: 36070428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized Trial.
    Gouëffic Y; Torsello G; Zeller T; Esposito G; Vermassen F; Hausegger KA; Tepe G; Thieme M; Gschwandtner M; Kahlberg A; Schindewolf M; Sapoval M; Diaz-Cartelle J; Stavroulakis K;
    Circulation; 2022 Nov; 146(21):1564-1576. PubMed ID: 36254728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial.
    Gray WA; Keirse K; Soga Y; Benko A; Babaev A; Yokoi Y; Schroeder H; Prem JT; Holden A; Popma J; Jaff MR; Diaz-Cartelle J; Müller-Hülsbeck S;
    Lancet; 2018 Oct; 392(10157):1541-1551. PubMed ID: 30262332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of the paclitaxel-eluting Eluvia stent for long femoropopliteal lesions in Asian patients with predominantly chronic limb-threatening ischemia.
    Kum S; Ipema J; Huizing E; Tan YK; Lim D; Lok IY; Hazenberg CE; Ünlü Ç
    Vasc Med; 2021 Jun; 26(3):267-272. PubMed ID: 33733963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Year Outcomes of the Eluvia Drug-Eluting Stent for the Treatment of Complex Femoropopliteal Lesions.
    Stavroulakis K; Torsello G; Bosiers M; Argyriou A; Tsilimparis N; Bisdas T
    JACC Cardiovasc Interv; 2021 Mar; 14(6):692-701. PubMed ID: 33736776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Femoropopliteal Artery Disease with Polymer-Coated Drug-Eluting Stent: 5-Year Results of a Prospective, Non-Randomized Study Including the Halo Phenomenon.
    Torsello GF; Stavroulakis K; Bisdas T; Cardona Y; Wichmann K; Torsello GB
    Cardiovasc Intervent Radiol; 2024 Feb; 47(2):177-185. PubMed ID: 38228879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1-Year All-Comers Analysis of the Eluvia Drug-Eluting Stent for Long Femoropopliteal Lesions After Suboptimal Angioplasty.
    Bisdas T; Beropoulis E; Argyriou A; Torsello G; Stavroulakis K
    JACC Cardiovasc Interv; 2018 May; 11(10):957-966. PubMed ID: 29798772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of a paclitaxel-eluting stent (Eluvia) compared to Zilver PTX for endovascular femoropopliteal intervention.
    Gray WA; Griffiths RI; Elroy PWM; Amorosi SL; McGovern AM; Jaff MR; Akehurst R; Müller-Hülsbeck S
    J Med Econ; 2022; 25(1):880-887. PubMed ID: 35703041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-Year Efficacy and Safety Results from the IMPERIAL Randomized Study of the Eluvia Polymer-Coated Drug-Eluting Stent and the Zilver PTX Polymer-free Drug-Coated Stent.
    Müller-Hülsbeck S; Benko A; Soga Y; Fujihara M; Iida O; Babaev A; O'Connor D; Zeller T; Dulas DD; Diaz-Cartelle J; Gray WA
    Cardiovasc Intervent Radiol; 2021 Mar; 44(3):368-375. PubMed ID: 33225377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 24-Month Efficacy and Safety Results from Japanese Patients in the IMPERIAL Randomized Study of the Eluvia Drug-Eluting Stent and the Zilver PTX Drug-Coated Stent.
    Iida O; Fujihara M; Kawasaki D; Mori S; Yokoi H; Miyamoto A; Kichikawa K; Nakamura M; Ohki T; Diaz-Cartelle J; Müller-Hülsbeck S; Gray WA; Soga Y
    Cardiovasc Intervent Radiol; 2021 Sep; 44(9):1367-1374. PubMed ID: 34235560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease.
    Müller-Hülsbeck S; Keirse K; Zeller T; Schroë H; Diaz-Cartelle J
    J Endovasc Ther; 2016 Oct; 23(5):701-7. PubMed ID: 27193308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-Year Late Lumen Loss between A Polymer-Coated Paclitaxel-Eluting Stent (Eluvia) and a Polymer-Free Paclitaxel-Coated Stent (Zilver PTX) for Femoropopliteal Disease.
    Soga Y; Fujihara M; Tomoi Y; Iida O; Ishihara T; Kawasaki D; Ando K
    J Atheroscler Thromb; 2020 Feb; 27(2):164-171. PubMed ID: 31257301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease).
    Lammer J; Zeller T; Hausegger KA; Schaefer PJ; Gschwendtner M; Mueller-Huelsbeck S; Rand T; Funovics M; Wolf F; Rastan A; Gschwandtner M; Puchner S; Ristl R; Schoder M
    J Am Coll Cardiol; 2013 Oct; 62(15):1320-7. PubMed ID: 23831445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness Study of Drug-Eluting and Bare-Metal Peripheral Artery Stents in Endovascular Femoropopliteal Artery Revascularization.
    Jeon-Slaughter H; Khalili H; Tsai S; Armstrong EJ; Shammas NW; Jawaid O; Lu H; Addo T; Gigliotti O; Abu-Fadel M; Banerjee S
    J Invasive Cardiol; 2018 Oct; 30(10):373-379. PubMed ID: 30279293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial.
    Gouëffic Y; Sauguet A; Desgranges P; Feugier P; Rosset E; Ducasse E; Kaladji A; Salomon du Mont L; Pernès JM; Commeau P; Lermusiaux P; Leclere B; Guyomarc'h B; Hoffmann CT; Maurel B
    JACC Cardiovasc Interv; 2020 Feb; 13(4):447-457. PubMed ID: 32081238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized clinical Trial Comparing drug Eluting Stent Zilver PTX® Versus Bare Metal Stent Zilver Flex® for Treatment of Lesions in Femoral and Popliteal Arteries in Chronic Limb Threatening Ischemia.
    Fransson T; Gottsäter A; Abdulrasak M; Malina M; Resch T
    Vasc Endovascular Surg; 2023 Oct; 57(7):706-716. PubMed ID: 37085152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of primary stent therapy for femoropopliteal peripheral arterial disease at 7 years.
    Stavroulakis K; Torsello G; Manal A; Schwindt A; Hericks C; Stachmann A; Schönefeld E; Bisdas T
    J Vasc Surg; 2016 Dec; 64(6):1696-1702. PubMed ID: 27575816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased mortality with paclitaxel-eluting stents is driven by lesion length.
    Mathlouthi A; Yei KS; Naazie I; Bertges DJ; Malas MB
    J Vasc Surg; 2021 Feb; 73(2):548-553.e2. PubMed ID: 32615286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Japanese Patients Treated in the IMPERIAL Randomized Trial Comparing Eluvia and Zilver PTX Stents.
    Soga Y; Fujihara M; Iida O; Kawasaki D; Hirano K; Yokoi H; Miyamoto A; Kichikawa K; Nakamura M; Ohki T; Diaz-Cartelle J; Gray WA; Müller-Hülsbeck S
    Cardiovasc Intervent Radiol; 2020 Feb; 43(2):215-222. PubMed ID: 31690980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Safety of a Paclitaxel-Eluting Stent for Superficial Femoral Artery Lesions up to 190 mm: One-Year Outcomes of the Single-Arm IMPERIAL Long Lesion Substudy of the Eluvia Drug-Eluting Stent.
    Golzar J; Soga Y; Babaev A; Iida O; Kawasaki D; Bachinsky W; Park J; Prem JT; Vermassen F; Diaz-Cartelle J; Müller-Hülsbeck S; Gray WA
    J Endovasc Ther; 2020 Apr; 27(2):296-303. PubMed ID: 31989856
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.